A phase I/II study of concurrent weekly docetaxel (Taxotere), androgen ablation, and adaptive external beam radiotherapy for localized high-risk adenocarcinoma of the prostate.

Trial Profile

A phase I/II study of concurrent weekly docetaxel (Taxotere), androgen ablation, and adaptive external beam radiotherapy for localized high-risk adenocarcinoma of the prostate.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Docetaxel (Primary) ; Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jun 2011 Planned end date changed from 1 Jun 2009 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top